Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prolactin bioassay and hyperprolactinemia.

C A Peabody1, P N Schultz, M D Warner

  • 1Department of Psychiatry, University of Texas Medical School, Houston.

Journal of Endocrinological Investigation
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of prolactin and growth hormone immuno- and bioactivities in the pituitary gland and serum of the squirrel monkey (Saimiri boliviensis boliviensis).

American journal of primatology·2020
Same author

Studies on the structure and physiology of salmon teleocalcin.

Fish physiology and biochemistry·2013
Same author

Bromocriptine inhibits galanin gene expression in the rat pituitary gland.

Molecular and cellular neurosciences·2009
Same author

Investigating the effect of remodelling signal type on the finite element based predictions of bone remodelling around the thrust plate prosthesis: a patient-specific comparison.

Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine·2005
Same author

Bone remodelling of a proximal femur with the thrust plate prosthesis: an in vitro case.

Computer methods in biomechanics and biomedical engineering·2004
Same author

Cyclic loading moves the peak stress to the cartilage surface in a biphasic model with isotropic solid phase properties.

Medical engineering & physics·2004
Same journal

Correction: Early in, early out: reproductive lifespan timing and cardiometabolic risk in women.

Journal of endocrinological investigation·2026
Same journal

Adult mice are more susceptible to high-fat diet-induced visceral adiposity and insulin resistance than juvenile mice.

Journal of endocrinological investigation·2026
Same journal

Lactobacillus gasseri alleviates type 2 diabetes via modulation of gut microbiota-host metabolic networks.

Journal of endocrinological investigation·2026
Same journal

Rare causes of exogenous Cushing's Syndrome: a challenge for endocrinologists.

Journal of endocrinological investigation·2026
Same journal

Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.

Journal of endocrinological investigation·2026
Same journal

4-Methylumbelliferone for type 1 diabetes therapy: evidence for β-cell protection via EGFR/PI3K/Akt signaling.

Journal of endocrinological investigation·2026
See all related articles

Dopamine agonist CV 205-502 effectively lowered prolactin (PRL) levels in hyperprolactinemia patients. However, the bioactivity of prolactin remained unchanged, suggesting treatment impacts overall levels but not intrinsic function.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Hyperprolactinemia is a condition characterized by elevated prolactin (PRL) levels.
  • Pituitary adenomas are a common cause of hyperprolactinemia.
  • Dopamine agonists are a primary treatment for hyperprolactinemia.

Purpose of the Study:

  • To evaluate the effect of the dopamine agonist CV 205-502 on prolactin (PRL) levels and bioactivity in patients with hyperprolactinemia.
  • To assess whether treatment with CV 205-502 alters the relative bioactivity of PRL.

Main Methods:

  • The Nb2 rat lymphoma bioassay (BA) and radioimmunoassay (RIA) were used to measure PRL levels and bioactivity.
  • Twenty-six subjects with hyperprolactinemia, including 17 with pituitary adenomas, were treated with CV 205-502.

Related Experiment Videos

  • PRL levels and bioactivity were assessed before and after treatment.

    • Main Results:

    • Radioimmunoassay (RIA) measured PRL levels significantly decreased after treatment with CV 205-502.
    • The ratio of bioassay (BA) to RIA prolactin (PRL) remained unchanged, indicating stable relative bioactivity.
    • Treatment with CV 205-502 effectively reduced overall PRL levels without altering its intrinsic biological activity.

    Conclusions:

    • Long-acting dopamine agonist CV 205-502 is effective in reducing serum prolactin levels in patients with hyperprolactinemia.
    • The bioactivity of prolactin is not significantly affected by treatment with CV 205-502.
    • This suggests that dopamine agonist therapy normalizes prolactin levels while preserving its functional capacity.